Jacobs Levy Equity Management Inc. Sells 663,410 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Jacobs Levy Equity Management Inc. trimmed its position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 50.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 662,981 shares of the company's stock after selling 663,410 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.66% of Acelyrin worth $2,082,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of Acelyrin during the fourth quarter valued at $33,000. 4WEALTH Advisors Inc. bought a new stake in Acelyrin during the 4th quarter valued at about $35,000. Hsbc Holdings PLC purchased a new stake in Acelyrin in the 4th quarter valued at about $36,000. RPO LLC purchased a new stake in Acelyrin in the 4th quarter valued at about $46,000. Finally, Intech Investment Management LLC grew its stake in Acelyrin by 71.0% in the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock worth $83,000 after acquiring an additional 11,040 shares in the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. This trade represents a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 13.60% of the company's stock.

Acelyrin Price Performance

Shares of NASDAQ:SLRN traded up $0.05 during trading on Wednesday, reaching $2.28. 4,076,442 shares of the company were exchanged, compared to its average volume of 1,235,275. The business's fifty day simple moving average is $2.39 and its 200-day simple moving average is $2.93. Acelyrin, Inc. has a 12-month low of $1.85 and a 12-month high of $7.25. The firm has a market capitalization of $229.97 million, a PE ratio of -0.93 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.40. On average, sell-side analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.